Clinic file

Hims

Reviewed by Editorial review in progress · Last updated 2026-07-12

The bottom line

No verdict has been issued yet.

This is a neutral factual record. Hims (hims.com) is the men's brand of Hims & Hers Health, Inc. (NYSE: HIMS), a publicly traded telehealth company headquartered in San Francisco; this record is scoped to its GLP-1 weight-loss program only. As of mid-2026 the weight-loss lineup is brand-name only: Wegovy pill (from $149/mo) and pen (from $199/mo), Ozempic pill (from $149/mo) and injection (from $199/mo), Zepbound vial and KwikPen (from $299/mo), Lilly's Foundayo pill (from $149/mo), and Mounjaro/Zepbound pens at $1,899/mo - all requiring a separately billed Weight Loss Membership ($39 first month, auto-renewing at $149/mo) that does not include or guarantee a prescription. Its own weight-loss page states the offering is 'not available in all 50 states,' so all-50 coverage is recorded as not confirmed even though its affiliated medical groups have providers in all 50 states. The compounded-semaglutide era that preceded this lineup generated the densest weight-loss-program controversy record of any clinic reviewed on this site, all of it precisely dateable: a Novo Nordisk partnership announced April 29, 2025 and publicly terminated June 23, 2025 over alleged 'illegal mass compounding' and 'deceptive marketing' (shares fell roughly a third); securities class actions filed June 25, 2025 (consolidated in N.D. Cal.) plus three derivative suits; FDA misbranding warning letters to both Hims and Hers dated September 9, 2025; a December 2025 FDA warning letter to its own 503B facility MedisourceRx over unreported patient hospitalization; a February 5, 2026 launch of a $49/mo compounded Wegovy-copy pill that was withdrawn two days later (February 7) after the FDA named the company in a February 6 enforcement statement and HHS referred it to the DOJ; a Novo patent suit filed February 9, 2026; an SEC enforcement investigation opened February 2026; and a consumer false-advertising class action filed February 20, 2026. On March 9, 2026 Hims and Novo settled - Novo dismissed its suit without prejudice and Hims agreed to stop advertising compounded GLP-1s and transition patients to branded drugs, retaining compounded access only for documented clinical necessity. The DOJ referral, SEC investigation, securities and consumer suits remained unresolved as of the access date.

The supply chain

You buy fromHimsThe brand: marketing, checkout, and the subscription.

Your clinician works forYou HealthA contract medical group named on the clinic's own site — the brand doesn't employ your clinician.

Your prescription is filled byStrive PharmacyNamed by the clinic's own disclosure — profiled in our pharmacy directory.

Licensed where you live?Check your stateEvery fill depends on the pharmacy holding a license in your state — verified below, state board by state board.

What checks out

No gate criteria passed yet.

What to watch

FDA misbranding warning letters over compounded semaglutide marketing (September 9, 2025). After reviewing hims.com in August 2025, the FDA cited the claims 'Same active ingredient as Ozempic and Wegovy' and 'Clinically proven ingredients' as false or misleading under FDCA sections 502(a) and 502(bb), because they implied an unapproved compounded product was the same as FDA-approved drugs. Parallel letters went to both the Hims (MARCS-CMS 716567) and Hers (716825) platforms as part of a roughly 50-company FDA sweep of compounded GLP-1 marketing; the company says it responded timely. The same equivalence claim is now the core allegation of a consumer false-advertising class action (Donoho et al. v. Hims & Hers, No. 1:26-cv-01954, filed February 20, 2026 in Illinois federal court) alleging the compounded product's synthetic manufacturing process yielded a meaningfully different, untested peptide.

FDA warning letter to Hims' own 503B compounding facility over an unreported patient hospitalization (December 2025). MedisourceRx (Los Alamitos, CA), the outsourcing facility Hims & Hers acquired in September 2024 and used to compound its injectable semaglutide, received an FDA warning letter citing failure to submit a required adverse-event report and deficient adverse-event reporting procedures under Section 503B, after a May-June 2025 inspection found a January 2025 case in which a patient was hospitalized for three nights with severe gastrointestinal effects after taking the compounded semaglutide and the event was not reported to the FDA within the required 15 days. The company disclosed the letter in its FY2025 10-K and says it responded timely and took corrective action; the FDA's satisfaction with the response was not yet public as of the access date.

Novo Nordisk publicly terminated its partnership over alleged 'illegal mass compounding and deceptive marketing' (June 23, 2025), triggering securities litigation and an SEC investigation. The collaboration - announced April 29, 2025, bundling brand Wegovy via NovoCare Pharmacy with a Hims membership from $599/mo - collapsed in under two months, with Novo alleging Hims sold compounded semaglutide at mass scale 'under the false guise of personalization' after the FDA declared the semaglutide shortage over, and that compounders' API comes from unapproved Chinese suppliers. HIMS shares fell roughly a third that day. Two securities class actions filed June 25, 2025 were consolidated as In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.; amended complaint January 29, 2026, class period April 29-June 22, 2025), three shareholder derivative suits followed (stayed as of the 10-K), and in February 2026 the SEC's Division of Enforcement opened an investigation into the company's public statements about compounded semaglutide and related business relationships. All were unresolved as of the access date.

Launched, then withdrew within two days, a $49 compounded copy of Novo's newly approved Wegovy pill under federal pressure, drawing a DOJ referral and a patent suit (February 5-9, 2026). Hims announced compounded semaglutide pills starting at $49/month on February 5, 2026, weeks after Novo's FDA-approved oral Wegovy launched at $149. On February 6 the FDA announced it would restrict GLP-1 APIs used in mass-marketed compounded drugs and named the company; the HHS General Counsel stated on X that HHS had referred the company to the Department of Justice for potential FDCA and Title 18 violations. Hims pulled the pill on February 7, and on February 9 Novo Nordisk filed a patent-infringement suit (Novo Nordisk A/S et al. v. Hims & Hers Health, Inc., No. 1:26-cv-0014, D. Del.) seeking an injunction through patent expiry in December 2031. The suit was dismissed without prejudice under the March 9, 2026 settlement in which Hims agreed to stop advertising compounded GLP-1s and shift to branded products; the DOJ referral's outcome was not public as of the access date.

Mandatory membership fee stacked on medication pricing, with a strict no-refund policy once medication ships. The advertised 'from $149/mo' medication prices exclude the required Weight Loss Membership, which is billed separately at $39 for the first month and auto-renews at $149/month, does not include or guarantee a prescription, and is non-refundable for partially used periods. Medication is not refundable after shipment, and Medication Plan refunds exist only in a 48-hour initial window or by canceling at least two days before renewal. Complaint snippets on the company's Trustpilot profile recur on exactly this membership step-up and billing friction (scores unverifiable because Trustpilot blocks fetching). The Terms also impose binding arbitration with a class-action waiver unless the customer opts out.

Who provides your care

Care is outsourced to You Health

A contract medical group named on Hims's own pages. The brand selling the subscription doesn't employ the clinician who prescribes.

You Health: “clinical services are provided by the following contracted medical groups: You Health of Alaska, P.C., You Health of California P.C., … You Health of Texas”
From Hims's own page.

Source: hims.com/terms-and-conditions (accessed 2026-07-23)

Why this matters

A contract medical group serves many brands at once. Your prescriber answers to the vendor's protocols and staffing, not to the clinic you pay — and if the brand switches vendors, your care relationship goes with it. It does not by itself disqualify a clinic, but it weighs against the verdict.

Trustpilot review integrity

Review integrity concern

72% of this company's reviews are organic (unprompted) — above our 40% threshold, the pattern most consistent with review gaming.

Score: 3.0 / 5 across 2,113 reviews (trailing 12 months)
Review source: 72% organic (unprompted) · 28% verified or invited (company-sent, post-transaction)
OrganicVerified / invited

Source: Trustpilot's own "Transparent Inviting" disclosure, company profile (accessed 2026-07-12).

Review integrity concern

72% of this company's Trustpilot reviews are organic (unprompted), above our 40% threshold. Verified and invited reviews both require a real completed transaction and the company choosing to send the invite, which makes them hard to fabricate at scale. A heavy skew toward organic, unprompted reviews is a known review-manipulation vector — it does not by itself disqualify a clinic, but it weighs against the verdict. See how we weigh this.

Corporate address transparency

Agent or mailbox address — no operating location listed

Virtual office / rented mailbox, found on the company's own site.

Legal entity: Hims & Hers Health, Inc.
Listed address: 2269 Chestnut Street, #523, San Francisco, CA 94123
Notes: A mail-drop storefront ("#523" is a mailbox) — but it is the company's address of record including SEC filings; Hims is a publicly traded (NYSE: HIMS), remote-first company, a different situation from an undisclosed shell.

Source: Privacy policy, mailing address (Attn: Privacy Officer) (accessed 2026-07-19)

Who fills your prescription

Hims is unusually vertically integrated for a GLP-1 telehealth brand: Hims & Hers Health, Inc. owns and operates its own pharmacy and manufacturing chain rather than only contracting out. Per its FY2025 Form 10-K, the company operates two licensed 503A mail-order pharmacies that fill solely for its own customers - Apostrophe Pharmacy LLC and XeCare, LLC, both now wholly-owned subsidiaries - plus a licensed 503B outsourcing facility, MedisourceRx (acquired September 2024 as Seaview Enterprises, LLC, for $31.0 million; Los Alamitos, CA), which compounded its injectable semaglutide, and a peptide manufacturing facility. The consumer Terms also name third-party partner pharmacies (EHT Pharmacy LLC dba Curexa, CD Pharmacy LLC dba Red Rock Pharmacy, AnazaoHealth Corporation, and Strive Specialties, Inc.). During the April-June 2025 Novo Nordisk bundle, brand-name Wegovy was dispensed through Novo's own NovoCare Pharmacy accessed via the Hims platform. Prescriptions are written by providers in affiliated 'You Health' professional medical groups; Hims & Hers states in its Terms that it is not itself a healthcare provider.

Strive Pharmacy503A · Strive Pharmacy LLC (dba Strive Compounding Pharmacy) · licensed in 1 of 50 states (unverified)PCAB/ACHC (self-reported, unverified) · NABP (self-reported, unverified) · LegitScript (self-reported, unverified)

What it's actually like

Pricing (per the archived hims.com/weight-loss page, June 17, 2026 snapshot, and Hims newsroom releases): medication prices are quoted 'medication only' and stack on top of a mandatory Hims Weight Loss Membership billed separately at $39 for the first month, auto-renewing at $149/month; the membership 'does not include or guarantee a prescription' and medication is not available without it. Current medications: Wegovy pill from $149/mo and pen from $199/mo (launched on the platform March 26, 2026), Ozempic pill from $149/mo and injection from $199/mo, Zepbound Vial and KwikPen from $299/mo, Foundayo pill (Lilly's oral tirzepatide-class product) from $149/mo, and Mounjaro or Zepbound pens at $1,899/mo. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and offered only where a provider finds clinical eligibility. No compounded GLP-1 appears in the June 2026 lineup, consistent with the March 9, 2026 strategic-shift commitment to stop advertising compounded GLP-1s; the company stated compounded access would remain for the limited set of customers whose clinical needs cannot be met by FDA-approved GLP-1s. Historically the program was built on compounded injectable semaglutide compounded at its own 503B (MedisourceRx), and briefly (February 5-7, 2026) a compounded oral semaglutide at $49 for the first month. Intake: an online intake reviewed by licensed providers in affiliated 'You Health' medical groups; the Terms state Hims & Hers is not itself a healthcare provider and prescriptions may be filled by and transferred among its named Pharmacies. States: the weight-loss page states the offering is 'not available in all 50 states' without publishing a state list, while the 10-K reports 1,586 providers across all 50 states platform-wide - so weight-loss-specific coverage is not confirmed. Refunds/cancellation (per Terms, June 2026 snapshot): the Weight Loss Membership and Medication Plan are separate subscriptions; no refunds for partially used periods; no refund for any medication after it has shipped; a Medication Plan refund is available only if an initial order is canceled within 48 hours of submitting payment or a renewal is canceled at least two days before the billing date. The Terms include a binding arbitration clause with a class-action waiver (opt-out available). A Trustpilot profile exists; recurring complaint themes in search-result snippets center on the $39-to-$149 membership step-up and billing/cancellation friction, though scores could not be independently verified because Trustpilot blocks fetching.

How we review. Every clinic must clear two gates: a credible compounding pharmacy, licensed in every state it ships to, and a clinic that supports long-term patient success. We pay for our own access and accept no payment, referral fees, or coupon arrangements from anyone we cover. See the methodology.